» Articles » PMID: 31163957

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy

Abstract

Purpose: BioPATH is a non-interventional study evaluating the relationship of molecular biomarkers (PTEN deletion/downregulation, PIK3CA mutation, truncated HER2 receptor [p95HER2], and tumor HER2 mRNA levels) to treatment responses in Asian patients with HER2+ advanced breast cancer treated with lapatinib and other HER2-targeted agents.

Materials And Methods: Female Asian HER2+ breast cancer patients (n=154) who were candidates for lapatinib-based treatment following metastasis and having an available primary tumor biopsy specimen were included. The primary endpoint was progression-free survival (PFS). Secondary endpoints were response rate, overall survival on lapatinib, correlation between biomarker status and PFS for any previous trastuzumab-based treatment, and conversion/conservation rates of the biomarker status between tissue samples collected at primary diagnosis and at recurrence/metastasis. Potential relationships between tumor mRNA levels of HER2 and response to lapatinib-based therapy were also explored.

Results: p95HER2, PTEN deletion/downregulation, and PIK3CA mutation did not demonstrate any significant co-occurrence pattern and were not predictive of clinical outcomes on either lapatinib-based treatment or any previous trastuzumab-based therapy in the metastatic setting. Proportions of tumors positive for p95HER2 expression, PIK3CA mutation, and PTEN deletion/down-regulation at primary diagnosis were 32%, 31.2%, and 56.2%, respectively. Despite limited availability of paired samples, biomarker status patterns were conserved in most samples. HER2 mRNA levels were not predictive of PFS on lapatinib.

Conclusion: The prevalence of p95HER2 expression, PIK3CA mutation, and PTEN deletion/downregulation at primary diagnosis were similar to previous reports. Importantly, no difference was observed in clinical outcome based on the status of these biomarkers, consistent with reports from other studies.

Citing Articles

Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis.

Rosin J, Svegrup E, Valachis A, Zerdes I Breast Cancer Res Treat. 2023; 201(2):161-169.

PMID: 37392328 PMC: 10361863. DOI: 10.1007/s10549-023-07010-1.


Comparison of Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations.

Chen J, Murugesan K, Newberg J, Sokol E, Savage H, Stout T JCO Precis Oncol. 2022; 6:e2200341.

PMID: 36446041 PMC: 9812634. DOI: 10.1200/PO.22.00341.


PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients.

Kim J, Lim A, You J, Lee J, Song S, Lee N Cancer Res Treat. 2022; 55(2):531-541.

PMID: 36097803 PMC: 10101795. DOI: 10.4143/crt.2022.221.


Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

Testa U, Castelli G, Pelosi E Med Sci (Basel). 2020; 8(1).

PMID: 32210163 PMC: 7151639. DOI: 10.3390/medsci8010018.

References
1.
Sutherland S, Ashley S, Miles D, Chan S, Wardley A, Davidson N . Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. Br J Cancer. 2010; 102(6):995-1002. PMC: 2844035. DOI: 10.1038/sj.bjc.6605586. View

2.
Razis E, Bobos M, Kotoula V, Eleftheraki A, Kalofonos H, Pavlakis K . Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat. 2011; 128(2):447-56. DOI: 10.1007/s10549-011-1572-5. View

3.
Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini P . Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res. 2010; 16(9):2688-95. PMC: 3243489. DOI: 10.1158/1078-0432.CCR-09-3407. View

4.
Park H, Sohn J, Kim S, Park S, Park H, Gho S . Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. Breast Cancer Res Treat. 2017; 163(2):255-262. DOI: 10.1007/s10549-017-4175-y. View

5.
Wang H . Lapatinib for the treatment of breast cancer in the People's Republic of China. Onco Targets Ther. 2014; 7:1367-73. PMC: 4125370. DOI: 10.2147/OTT.S60586. View